Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.15M | 643.00K | 1.81M | 1.63M | 1.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.07M | 1.45M | 2.45M | 2.49M | 2.72M |
| Operating Income | -2.07M | -1.45M | -2.45M | -2.49M | -2.72M |
| Income Before Tax | -2.37M | -1.82M | -3.63M | -2.83M | -2.84M |
| Income Tax Expenses | -- | 9.00K | 5.00K | 5.00K | 5.00K |
| Earnings from Continuing Operations | -2.37M | -1.83M | -3.64M | -2.83M | -2.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.37M | -1.83M | -3.64M | -2.83M | -2.84M |
| EBIT | -2.07M | -1.45M | -2.45M | -2.49M | -2.72M |
| EBITDA | -2.03M | -1.45M | -2.44M | -2.48M | -2.67M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 4.40B | 4.43B | 3.67B | 1.83B | 1.83B |
| Average Diluted Shares Outstanding | 220.24B | 221.38B | 183.54B | 91.50B | 91.50B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
